Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Petrini

Showing results (131-140 of 254) with videos related to

Pageof 26
Sort By:
Transplant Immunology|January 18, 2006
Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity settingSara Galimberti, Edoardo Benedetti, Fortunato Morabito, et al.
American Journal of Hematology|January 23, 2010
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematologyUmberto Vitolo, Giovanni Barosi, Stefano Fanti, et al.
European Journal of Haematology|November 26, 2019
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patientsElisabetta Antonioli, Chiara Nozzoli, Gabriele Buda, et al.
Leukemia Research|March 30, 2007
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemiaGabriele Buda, Enrico Orciuolo, Sara Galimberti, et al.
Leukemia Research|February 13, 2010
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with ImatinibGiovanni Carulli, Elisa Cannizzo, Virginia Ottaviano, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2004
Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H)Sara Galimberti, Giulia Cervetti, Nadia Cecconi, et al.
Plos One|September 12, 2013
Use of autologous human mesenchymal stromal cell/fibrin clot constructs in upper limb non-unions: long-term assessmentStefano Giannotti, Luisa Trombi, Vanna Bottai, et al.
American Journal of Clinical Pathology|February 17, 2012
The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical modelElisa Cannizzo, Giovanni Carulli, Luigi Del Vecchio, et al.
Pharmacogenetics and Genomics|April 15, 2008
MDR1 diplotypes as prognostic markers in multiple myelomaValentina Maggini, Gabriele Buda, Alessandro Martino, et al.
Biomedical Materials (Bristol, England)|July 17, 2014
Processing large-diameter poly(L-lactic acid) microfiber mesh/mesenchymal stromal cell constructs via resin embedding: an efficient histologic methodDelfo D'Alessandro, Gianni Pertici, Stefania Moscato, et al.
Pageof 26

Showing results (131-140 of 254) with videos related to

Sort By:
Pageof 26
Transplant Immunology|January 18, 2006
Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity settingSara Galimberti, Edoardo Benedetti, Fortunato Morabito, et al.
American Journal of Hematology|January 23, 2010
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematologyUmberto Vitolo, Giovanni Barosi, Stefano Fanti, et al.
European Journal of Haematology|November 26, 2019
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patientsElisabetta Antonioli, Chiara Nozzoli, Gabriele Buda, et al.
Leukemia Research|March 30, 2007
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemiaGabriele Buda, Enrico Orciuolo, Sara Galimberti, et al.
Leukemia Research|February 13, 2010
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with ImatinibGiovanni Carulli, Elisa Cannizzo, Virginia Ottaviano, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2004
Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H)Sara Galimberti, Giulia Cervetti, Nadia Cecconi, et al.
Plos One|September 12, 2013
Use of autologous human mesenchymal stromal cell/fibrin clot constructs in upper limb non-unions: long-term assessmentStefano Giannotti, Luisa Trombi, Vanna Bottai, et al.
American Journal of Clinical Pathology|February 17, 2012
The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical modelElisa Cannizzo, Giovanni Carulli, Luigi Del Vecchio, et al.
Pharmacogenetics and Genomics|April 15, 2008
MDR1 diplotypes as prognostic markers in multiple myelomaValentina Maggini, Gabriele Buda, Alessandro Martino, et al.
Biomedical Materials (Bristol, England)|July 17, 2014
Processing large-diameter poly(L-lactic acid) microfiber mesh/mesenchymal stromal cell constructs via resin embedding: an efficient histologic methodDelfo D'Alessandro, Gianni Pertici, Stefania Moscato, et al.
Pageof 26